Clinical trials: Metastatic Breast Cancer, open to volunteers
Breast Cancer
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%.
- Trial name
- NCT04646759
- Testing
- Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Leptomeningeal Metastasis of HER2-positive Breast Cancer
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis
- Trial name
- NCT07263425
- Testing
- Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
The goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer.
- Trial name
- ARGUS project (NCT07244094)
- Testing
- Diagnostic Test: AI-Based Spatial Pathomic Analysis
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
Metastatic Breast Cancer With HER2 Positive
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy.
- Trial name
- NCT07132242
- Testing
- SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg
- Volunteers
- 84 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Triple-negative Breast Cancer
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
- Trial name
- NCT06471205
- Testing
- BL-B01D1, PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase…
- Trial name
- Pangeia-2 (NCT06417801)
- Where
- 6 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Stage IV Breast Cancer AJCC V7
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered…
- Trial name
- ACCESS (NCT06405828)
- Testing
- ACCESS Supportive Care, Phone sessions
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Brain Metastasis
Brain Metastasis Development Mechanism in BCBM Patients
This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis
- Trial name
- NCT06330870
- Testing
- WGS/TME evaluation
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Metastatic Breast Cancer
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as…
- Trial name
- TARGET-PC (NCT06795529)
- Testing
- Palliative Care Intervention, "TARGET-PC", Enhanced Usual Care
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer, End of Life
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and…
- Trial name
- NCT05440929
- Testing
- Clinician Qualitative Interview
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
This is a prospective, multicenter, single-arm study designed to verify the efficacy and safety of trastuzumab deruxtecan (T-DXd) in subjects with hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer who…
- Trial name
- Veri-HER2UL (NCT07782086)
- Testing
- Trastuzumab Deruxtecan (T-DXd, ENHERTU®)
- Where
- 14 sites in China
- Volunteers
- 30 people
- Sponsor
- Shuangyue Liu
TNBC
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative…
- Trial name
- NCT07376629
- Testing
- HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxel
- Where
- 23 sites in China
- Volunteers
- 60 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Metastatic Breast Cancer
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment…
- Trial name
- NCT06598046
- Testing
- Utidelone and capecitabine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms, Liver Neoplasms
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver…
- Conditions
- Breast Neoplasms, Liver Neoplasms, Metastasis
- Trial name
- NCT06567353
- Testing
- Multi-mode tumor treatment system, Radiofrequency ablation therapeutic apparatus
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Osteoporosis Secondary, Breast Cancer Females
Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass…
- Trial name
- Synostea (NCT07256769)
- Testing
- Group 1: calcium carbonate/cholecalciferol, Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol)
- Where
- 2 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Regina Elena Cancer Institute
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.